Medical Condition News

RSS

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting.

11 Dec 2012

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Updated results from a Phase Ib/II clinical trial indicates that a novel therapeutic agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

11 Dec 2012

Traumatic brain injury incidence: an interview with Professor Valery Feigin

Traumatic brain injury can be defined as an injury to the brain due to mechanical forces. Mechanical forces usually include falls, car accidents, accidental forces from another person or animal. It also includes sports-related brain injuries.

11 Dec 2012

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Researchers conducting a preclinical study in mice successfully used targeted molecular therapy to block mostly untreatable nerve tumors that develop in people with the genetic disorder Neurofibromatosis 1 (NF1).

11 Dec 2012

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Research unveils key gaps in continuity of care for sickle cell patients

Research unveiling key gaps in continuity of care for sickle cell patients transitioning from pediatric to adult care will be presented this week during the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

Link between internet use and reduced cancer fatalism

Many Americans have fatalistic views on cancer prevention-they believe that getting cancer is a matter of luck or fate. Recent research, published in the Journal of Communication, found that people who use the internet to inquire about their health are more likely to have a positive outlook on cancer prevention and diagnosis.

11 Dec 2012

uniQure commences acute intermittent porphyria Phase I clinical trial

uniQure B.V., a leader in the field of human gene therapy, today announced the start of its Phase I clinical trial in acute intermittent porphyria (AIP) with the treatment of the first patient.

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Researchers at Mayo Clinic in Florida have uncovered a toxic cellular process by which a protein that maintains the health of neurons becomes deficient and can lead to dementia.

11 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

Employing a combination of imaging and biomarker tests improves the ability of doctors to predict Alzheimer's in patients with mild cognitive impairment, according to researchers at Duke Medicine.

11 Dec 2012

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

Forest Laboratories, Inc. and Almirall, S.A. announced today that Tudorza Pressair (aclidinium bromide inhalation powder) 400mcg is now available in pharmacies throughout the United States.

11 Dec 2012

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy.

11 Dec 2012

Medical Condition News

Study finds high serum galectin-1 levels in Hodgkin lymphoma patients

Ibrutinib highly active and well tolerated in patients with chronic lymphocytic leukemia

Traumatic brain injury incidence: an interview with Professor Valery Feigin

Pfizer's PD0325901 experimental drug blocks untreatable NF1 tumors

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Research unveils key gaps in continuity of care for sickle cell patients

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Link between internet use and reduced cancer fatalism

uniQure commences acute intermittent porphyria Phase I clinical trial

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Lack of TDP-43 protein can lead to frontotemporal dementia/ALS

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Combination of imaging and biomarker tests helps predict Alzheimer's in patients with MCI

Almirall, Forest Laboratories' Tudorza Pressair now available in the U.S. pharmacies

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Strong association between bedroom TV viewing and childhood obesity

Overweight women not receiving proper advice on healthy weight gains during pregnancy

GSK, Fred Hutch to develop therapeutics against facioscapulohumeral muscular dystrophy

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Latest News